Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Life ; 16(5): 799-805, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-37520481

RESUMO

Methamphetamine use can induce psychosis resembling acute schizophrenia spectrum psychosis, making it challenging to differentiate between the two based on symptoms alone. Brain-derived neurotrophic factor (BDNF) exerts a critical role in hippocampal neural plasticity, influencing critical cognitive functions such as memory and learning. This study aimed to determine the role of serum BDNF levels in schizophrenia and methamphetamine addiction. A case-control study was conducted involving 50 patients with schizophrenia, 50 patients with methamphetamine addiction, and 50 healthy control subjects recruited from Ibn-Rushed Psychiatric Teaching Hospital in Baghdad. Cognitive impairment was assessed using the Mini-Mental State Examination (MMSE), while serum BDNF levels were measured using ELISA following standardized protocols. The findings revealed significantly lower median levels of BDNF (0.36 pg/ml) in patients with schizophrenia compared to both the control group (0.51 pg/ml) and the methamphetamine group (0.72 pg/ml). Moreover, there was a significant difference observed between the methamphetamine group and the control group. At a cut-off value of BDNF=0.37 pg/ml, the sensitivity and specificity of BDNF in differentiating between schizophrenia and methamphetamine addiction were 84% and 70%, respectively. Serum level of BDNF could be used to differentiate between schizophrenia and methamphetamine addiction when clinical distinctions are challenging to detect.


Assuntos
Transtornos Relacionados ao Uso de Anfetaminas , Disfunção Cognitiva , Metanfetamina , Esquizofrenia , Humanos , Transtornos Relacionados ao Uso de Anfetaminas/complicações , Fator Neurotrófico Derivado do Encéfalo , Estudos de Casos e Controles , Metanfetamina/efeitos adversos , Esquizofrenia/diagnóstico
2.
J Med Life ; 16(3): 463-470, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37168312

RESUMO

Nicotine dependence (ND) and visceral adiposity are emerging as independent risk factors for cardiovascular diseases, including carotid artery stenosis (CAS). This study aimed to determine the relationship between ND and the contribution of abdominal fat to the onset of CAS, which is indicated by a luminal narrowing of at least 60% as determined by duplex and/or Doppler ultrasound. We prospectively collected data from 60 patients with CAS and 60 age- and gender-matched healthy subjects. The Fagerström Test for Nicotine Dependence (FTND), a common research tool, was used in the study. The original questionnaire was designed to gather social and demographic data. Anthropometric measurements, visceral adiposity index (VAI), and lipid accumulation products (LAP) were used to assess obesity. Most patients showed a high or mild-moderate degree of ND: 46.67% and 35%, respectively. The median visceral adiposity index (VAI) and lipid accumulation product (LAP) in patients was 3.92 and 32.83, respectively. Prolonged smoking duration, increased intensity, and high ND are hallmarks of CAS patients.


Assuntos
Estenose das Carótidas , Tabagismo , Humanos , Adiposidade , Circunferência da Cintura , Estenose das Carótidas/diagnóstico por imagem , Estenose das Carótidas/epidemiologia , Estenose das Carótidas/etiologia , Índice de Massa Corporal , Obesidade Abdominal/complicações , Obesidade Abdominal/diagnóstico por imagem , Fatores de Risco
3.
J Med Life ; 16(2): 284-289, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36937471

RESUMO

Alzheimer's disease (AD) dementia is the most frequent cause of neurodegenerative dementia. The cognitive and behavioral symptoms associated with this disorder often have overlapping characteristics, potentially resulting in delayed diagnosis or misdiagnosis. This study aimed to assess the level of peripheral blood neurofilament light chain (NfL) and total tau (t-tau) protein in AD patients and investigate their relationship with cognitive impairment. The study included 80 participants of both sexes between the ages of 60 to 85 years. The participants were divided into two groups, consisting of 40 individuals in the control group (mean age 75±6.6 years) who had no cognitive or functional impairments and 40 AD patients (mean age 74.98±5.03 years). This study utilized the DSM-5 diagnostic criteria for major or mild neurocognitive disorder attributed to Alzheimer's disease (AD). The clinical and biochemical features of all participants were documented, and the Alzheimer's disease Assessment Scale cognitive subscale (ADAS-cog) scores were evaluated. Sandwich ELISA was employed to determine serum NfL and t-tau protein levels. The median serum NfL and t-tau protein levels in AD patients were significantly higher than those of the controls (47.84 pg/ml versus 17.66 pg/ml and 12.05 pg/ml versus 11.13 pg/ml, respectively). Age was positively correlated with NfL, t-tau levels, and ADAS-cog. Although elevated NfL and t-tau protein levels may play a role in disease progression, their diagnostic value for AD was limited.


Assuntos
Doença de Alzheimer , Disfunção Cognitiva , Masculino , Feminino , Humanos , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico , Proteínas tau , Filamentos Intermediários , Peptídeos beta-Amiloides , Cognição , Disfunção Cognitiva/diagnóstico , Biomarcadores
4.
Nephrology (Carlton) ; 24(1): 17-20, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29055055

RESUMO

AIM: This case/control study aimed to assess the impact of two single nucleotide polymorphisms (SNPs) in the promoter region of CDH1 gene (-160C>A and -347G>GA) on urinary stone formation in a sample of Iraqi children. METHODS: Forty-seven children with urolithiasis and 50 age- and gender-matched healthy controls were included in the study. DNA was isolated from peripheral blood and direct sequencing was used for genotyping. RESULTS: The homozygous genotype of the SNP CHD1 -160C>A was more frequent in control than cases (18% vs. 6.38%) with significant difference (OR = 0.229, 95%CI = 0.056-0.943, P = 0.041). Furthermore, cases showed significantly less frequency of the mutant allele (allele A) of this SNP (OR = 0.403, 95%C = 0.210-0.776, P = 0.007). CONCLUSION: These results strongly indicate a protective role of allele A of the SNP CHD1 -160C>A against urinary calculi formation in children.


Assuntos
Antígenos CD/genética , Caderinas/genética , Polimorfismo de Nucleotídeo Único , Urolitíase/genética , Fatores Etários , Estudos de Casos e Controles , Criança , Feminino , Frequência do Gene , Estudos de Associação Genética , Predisposição Genética para Doença , Heterozigoto , Homozigoto , Humanos , Iraque/epidemiologia , Masculino , Fenótipo , Regiões Promotoras Genéticas , Fatores de Proteção , Fatores de Risco , Urolitíase/diagnóstico , Urolitíase/epidemiologia , Urolitíase/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...